docetaxel anhydrous has been researched along with liraglutide in 1 studies
| Studies (docetaxel anhydrous) | Trials (docetaxel anhydrous) | Recent Studies (post-2010) (docetaxel anhydrous) | Studies (liraglutide) | Trials (liraglutide) | Recent Studies (post-2010) (liraglutide) |
|---|---|---|---|---|---|
| 12,110 | 3,216 | 6,920 | 2,404 | 481 | 2,154 |
| Protein | Taxonomy | docetaxel anhydrous (IC50) | liraglutide (IC50) |
|---|---|---|---|
| Glucagon-like peptide 1 receptor | Homo sapiens (human) | 0.0024 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Eftekhari, S; Montazeri, H; Tarighi, P | 1 |
1 other study(ies) available for docetaxel anhydrous and liraglutide
| Article | Year |
|---|---|
Synergistic anti-tumor effects of Liraglutide, a glucagon-like peptide-1 receptor agonist, along with Docetaxel on LNCaP prostate cancer cell line.
Topics: Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Cell Line, Tumor; Cell Survival; Docetaxel; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; Drug Therapy, Combination; Gene Expression Regulation; Glucagon-Like Peptide-1 Receptor; Humans; Liraglutide; Male; MAP Kinase Signaling System; Mitogen-Activated Protein Kinase 3; Prostatic Neoplasms; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; RNA, Messenger | 2020 |